Capricor Therapeutics is UNDERVALUED at 8.08 per share with modest projections ahead. Capricor Therapeutics is dangerous given 1 month investment horizon.
Capricor Therapeutics secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had 0.12% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use
Capricor Therapeutics market data together with company specific
technical indicators. We were able to collect and analyze data for twenty-seven different
technical indicators, which can help you to evaluate if expected returns of 3.89% are justified by taking the suggested risk. Use Capricor Therapeutics Risk Adjusted Performance of 0.2156,
downside deviation of 6.49, and Mean Deviation of 10.51 to evaluate company specific risk that cannot be
diversified away.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Capricor Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Capricor Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Capricor Therapeutics investors may use each financial statement separately, they are all related. The changes in Capricor Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Capricor Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Capricor Therapeutics
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Capricor Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Capricor Therapeutics shares is the value that is considered the true value of the share. If
the intrinsic value of Capricor is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Capricor Therapeutics. Please read more on our
fundamental analysis page.
How effective is Capricor Therapeutics in utilizing its assets?
Capricor Therapeutics reports assets on its Balance Sheet. It represents the amount of Capricor resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Capricor Therapeutics aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Capricor volatility, please check the breakdown of all its
fundamentals.
Are Capricor Therapeutics Earnings Expected to grow?
The
future earnings power of Capricor Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Capricor Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Capricor Therapeutics
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Capricor
expected earnings.
Capricor Therapeutics Gross Profit
Capricor Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Capricor Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Capricor Therapeutics Gross Profit growth over the last 10 years. Please check Capricor Therapeutics'
gross profit and other
fundamental indicators for more details.
Going after Capricor Financials
The latest price spikes of Capricor Therapeutics could raise concerns from retail investors as the firm closed today at a share price of
5.83 on
9,352,178 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
August. The stock standard deviation of daily returns for 30 days investing horizon is currently 32.02. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Capricor Therapeutics partners.
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Capricor Therapeutics has an asset utilization ratio of 3.92 percent. This connotes that the company is making $0.0392 for each dollar of assets. An increasing asset utilization means that Capricor Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 10.58 Million | 93.12 |
| Assets Non Current | 775,904 | 6.83 |
| Goodwill | 6,665.92 | 0.0586 |
Over 3 percent spike for Capricor Therapeutics. What does it mean for retail investors?
Latest kurtosis is at 58.35. Capricor Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Capricor Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Capricor Therapeutics volatility.
The Bottom Line
While some other firms within the biotechnology industry are still a little expensive, even after the recent corrections, Capricor Therapeutics may offer a potential longer-term growth to retail investors. To conclude, as of the 25th of July 2020, our present 30 days buy-or-sell advice on the enterprise is
Strong Sell. However, we believe Capricor Therapeutics is currently
undervalued with
high odds of distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Capricor Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com